{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:49Z","timestamp":1785168289833,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T00:00:00Z","timestamp":1511827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:p>We evaluate the impact of ledipasvir on both tenofovir plasma trough concentration and estimated glomerular renal function in human immunodeficiency virus\u2013hepatitis C virus coinfected patients receiving a tenofovir\u2010based antiretroviral regimen and treated with ledipasvir\/sofosbuvir. Twenty\u2010six patients [81% male, median age: 51 years; hepatitis C virus genotype 1(75%)\/4(15%)] were included. Tenofovir trough concentration (interquartile range) increased from 78\u00a0ng\u00a0ml<jats:sup>\u20131<\/jats:sup> (53\u2013110) at baseline to 141\u00a0ng\u00a0ml<jats:sup>\u20131<\/jats:sup> (72\u2013176) at 1 month (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.003). No significant difference on estimated glomerular renal function using both Cockroft\u2013Gault and Modification of Diet in Renal Disease formulae, respectively, [median (interquartile range)] was observed between baseline [101.3\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (91.1\u2013114.1); 95.6\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (86.5\u2013111.2)], 1 month [102.4\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (89.8\u2013112.9), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.26; 92.5\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (88.1\u2013114.3), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.27], end\u2010of\u2010treatment [96.5\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (82.4\u2013115.4), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.39; 95.4\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (84.2\u2013105.4), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.16] and 12 weeks after the end of treatment [100.5\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (83.3\u2013111.9), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.24; 93.4\u00a0ml\u00a0min<jats:sup>\u20131<\/jats:sup> (82.2\u2013103.5), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.16]. Three patients progressed from chronic kidney disease stage 1 to stage 2 at 12 weeks post\u2010treatment. A significant increase in tenofovir exposure through P\u2010glycoprotein inhibition by ledipasvir was confirmed without significant impact on glomerular renal function in our population with normal renal function or mild renal impairment.<\/jats:p>","DOI":"10.1111\/bcp.13450","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T14:56:39Z","timestamp":1507906599000},"page":"404-409","source":"Crossref","is-referenced-by-count":12,"title":["Ledipasvir and tenofovir drug interaction in human immunodeficiency virus\u2013hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety"],"prefix":"10.1111","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0943-9648","authenticated-orcid":false,"given":"Caroline","family":"Solas","sequence":"first","affiliation":[{"name":"Aix\u2010Marseille Univ, CRO2 \u2010 INSERM, UMR911  Marseille France"},{"name":"APHM, H\u00f4pital La Timone, Laboratoire de Pharmacocin\u00e9tique et Toxicologie  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Bregigeon","sequence":"additional","affiliation":[{"name":"APHM Sainte\u2010Marguerite, Service d'Immuno\u2010h\u00e9matologie clinique  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Faucher\u2010Zaegel","sequence":"additional","affiliation":[{"name":"APHM Sainte\u2010Marguerite, Service d'Immuno\u2010h\u00e9matologie clinique  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Quaranta","sequence":"additional","affiliation":[{"name":"APHM, H\u00f4pital La Timone, Laboratoire de Pharmacocin\u00e9tique et Toxicologie  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Obry\u2010Roguet","sequence":"additional","affiliation":[{"name":"APHM Sainte\u2010Marguerite, Service d'Immuno\u2010h\u00e9matologie clinique  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Tamalet","sequence":"additional","affiliation":[{"name":"IHU M\u00e9diterran\u00e9e Infection, Aix\u2010Marseille Univ., AP\u2010HM, URMITE UM 63 CNRS 7278 IRD 198 INSERM 1095  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[{"name":"Aix\u2010Marseille Univ, CRO2 \u2010 INSERM, UMR911  Marseille France"},{"name":"APHM, H\u00f4pital La Timone, Laboratoire de Pharmacocin\u00e9tique et Toxicologie  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Poizot\u2010Martin","sequence":"additional","affiliation":[{"name":"APHM Sainte\u2010Marguerite, Service d'Immuno\u2010h\u00e9matologie clinique  Marseille France"},{"name":"INSERM U912 (SESSTIM)  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.09.001"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000185"},{"key":"e_1_2_9_5_1","unstructured":"European Medicines Agency.Harvoni. Summary of Product characteristics. Available athttp:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/003850\/WC500177995.pdf(last accessed 13 January 2017)."},{"issue":"1","key":"e_1_2_9_6_1","first-page":"1976","article-title":"Drug\u2013drug interaction profile of the fixed\u2010dose combination tablet ledipasvir\/sofosbuvir","volume":"60","author":"German P","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_9_7_1","unstructured":"GermanP PangP WestS HanL SajwaniK MathiasA.Drug interactions between direct\u2010acting anti\u2010HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract O_06]. Presented at: 15thInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. Washington 2014."},{"key":"e_1_2_9_8_1","unstructured":"GarrissonK CustodioJ PangP DasM ChengF MaG et al.Drug interactions between anti\u2010HCV antivirals ledipasvir\/sofosbuvir and integrase strand transfer inhibitor\u2013based regimens [abstract 71]. Presented at: 16thInternational Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. Washington 2015."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e32833202e2"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2761"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31827ce4ee"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2009.00719.x"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7599.2002.tb00119.x"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv1037"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13355"},{"key":"e_1_2_9_16_1","unstructured":"European Medicines Agency.Viread. Summary of Product characteristics. Available athttp:\/\/www.ema.europa.eu\/docs\/fr_FR\/document_library\/EPAR_-_Product_Information\/human\/000419\/WC500051737.pdf(last accessed 05 January 2017)."},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00251-06"},{"key":"e_1_2_9_18_1","article-title":"Tenofovir nephrotoxicity: 2011 update","volume":"2011","author":"Fernandez\u2010Fernandez B","year":"2011","journal-title":"AIDS Res Treat"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1086\/376643"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1086\/499048"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000033"},{"key":"e_1_2_9_22_1","unstructured":"MorlatP.Prise en charge m\u00e9dicale des personnes vivant avec le VIH. Recommandations du groupe d'experts. Paris FRANCE: Minist\u00e8re des affaires sociales et de la Sant\u00e9. Conseil national du Sida. Agence nationale de recherches sur le sida et les h\u00e9patites virales. Rapport2013. Available athttp:\/\/social-sante.gouv.fr\/IMG\/pdf\/Rapport_Morlat_2013_Mise_en_ligne.pdf(last accessed 5 January 2017)"},{"key":"e_1_2_9_23_1","unstructured":"Vivancos\u2010GallegoMJ MorenoA P\u00e9rez\u2010EliasMJ QueredaC D\u00edaz De SantiagoA CasadoJL et al.Real\u2010life renal safety of \u201cboosted TDF\u201d in HIV\/HCV\u2010patients on SOF\/LDV [abstract 452]. Presented at: 23rdConference on Retroviruses and Opportunistic Infections. Boston 2016."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1803"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)00024-2"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000908"},{"key":"e_1_2_9_27_1","unstructured":"MogalianE StammLM OsinusiA ShenG SajwaniK McNallyJ et al.Drug interaction studies between sofosbuvir\/velpatasvir and boosted HIV ARV regimens [abstract 100]. Presented at: 23rdConference on Retroviruses and Opportunistic Infections. Boston 2016."}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13450","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T09:38:44Z","timestamp":1695893924000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,28]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1111\/bcp.13450"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13450","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,28]]}}}